Start the conversation
Investing icon Peter Lynch had a key tip for investors who were looking to cut through the uncertainty to find winning stocks.
His advice: Invest in what you know.
It's a great bit of advice - even when talking about tech stocks.
In a wild-and-wooly market like the one we're navigating now, focusing on a company whose products, services, and technologies you know, like, and use can give you one heck of a competitive advantage: You'll zero in on discount stocks before the deep-pocketed investment pros even realize there's a bargain to grab.
Today, I'm going to tell you all about one such tech play. It's a company I've been following for more than 30 years. And I've been using its technologies for almost as long.
In short, I'm going to tell you all about a stock that I know.
And I'll do more than just tell you about the company. I'm also going to walk you through the five "screens" that explain why this beaten-down tech leader should be on your personal "watch list" right now.
By the time we're done, if you decide to move on this stock, you'll be investing in what you know, too...
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.
Or to contact Money Morning Customer Service, click here.